- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04336501
Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation
December 15, 2020 updated by: Beijing Immunochina Medical Science & Technology Co., Ltd.
Efficacy Study About Donor Derived CD19-target T Cell to Treat B-ALL Post Hematopoietic Stem Cell Transplantation
Efficacy study about donor derived CD19-target T cell to treat B-ALL post hematopoietic stem cell transplantation
Study Overview
Detailed Description
Allogeneic hematopoietic stem cell transplantation (allo-hsct) for the treatment of refractory recurrent acute b-lymphoblastic leukemia (b-all), the overall survival rate of 3 years after transplantation was about 10%.
The overall survival rate at 3 years was about 70 percent.
In the early stage, the investigators established the monitoring method of leukemia micro-residual disease, effectively screened out the high-risk group of recurrence, combined with the new relapse treatment method, successfully implemented the stratification and even personalized dry prediction of leukemia recurrence for the first time in the world, and reduced the recurrence rate of the high-risk group by 30%.
However, the therapeutic targeting is not strong, and up to 30% of patients will develop graft versus host disease, which seriously affects the survival of patients.
The use of CAR repair T cells (CAR T) to target CD19 in the treatment of refractory recurrent b-all was effective, and the use of CAR T in the treatment of recurrent b-all after transplantation did not increase the risk of GVHD.
This clinical study mainly discussed the safety and efficacy of donor targeted cd19-t cells after allo-hsct in the treatment of acute b-lymphocytic leukemia with minimal residual disease.
It is expected that the recurrence rate will be reduced while the incidence of acute GVHD after transplantation will not be increase
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: xiang yu zhao, MD
- Phone Number: 13520122292
- Email: xyz80421@126.com
Study Contact Backup
- Name: zheng li xu
- Phone Number: 13501338951
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 000000
- Recruiting
- Peking University people's hospita
-
Contact:
- xiang yu zhao, MD
- Phone Number: 13520122292
- Email: xyz@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 65 years (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- To be aged 3 to 65 years
- It was consistent with the diagnosis of CD19+ B-All with MRD+ in allo- hsct transplantation
- The immunotyping was determined to be CD19+ B-All
- The T lymphocytes in the subjects were 100% donor T lymphocytes
- No chemotherapy or antibody treatment was received 2 weeks before cell therapy
- Left ventricular ejection fraction (LVEF) ≥50% and centerless inclusion were diagnosed by echocardiography
- The subjects had no pulmonary active infection
- Blood oxygen saturation at the fingertips ≥ 92%
- Estimated survival of >3 months
- ECOG physical condition level 0~1
Exclusion Criteria:
- Unwilling to accept IM19 CAR-T cell therapy, do not agree to signInformed consent of subject
- Subjects are allergic to the components of cellular products
- Total serum bilirubin ≥ 2.0mg/dl、Serum albumin < 35g/L、ALT and AST were more than 3 times of the upper limit of the normal range. Blood creatinine ≥ 2.0mg/dl;Platelet < 20 x 109 / L
- Subjects had activity level II-IV aGVHD, or activityModerate to severe cGVHD
- The subjects had a severe failure to control the infection
- Subject with known central nervous system leukemia (CNS2 or CNS3)
- Subjects were treated with CAR T cells or DLT after transplantation
- The subjects developed bone marrow failure syndrome after allo-hsct transplantation
- The subjects had previously received other gene treatments
- The subjects had a history of alcohol, drug use or mental illness
- Subjects were enrolled in any other clinical investigator within 1 month prior to screening
- Female subjects: 1) were pregnant/lactating, or 2) had a pregnancy plan during the study period,Or 3) fertile and unable to use effective contraception
- The researchers believe there are other conditions that may not be appropriate for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: IM19 CAR-T group
Subject will be treated with IM19 car-t cells
|
All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR at 6 month
Time Frame: 6 months
|
Objective response at 6 month
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: xiang yu zhao, MD, Peking University people's hospita
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2019
Primary Completion (ANTICIPATED)
December 1, 2021
Study Completion (ANTICIPATED)
December 1, 2021
Study Registration Dates
First Submitted
April 3, 2020
First Submitted That Met QC Criteria
April 6, 2020
First Posted (ACTUAL)
April 7, 2020
Study Record Updates
Last Update Posted (ACTUAL)
December 17, 2020
Last Update Submitted That Met QC Criteria
December 15, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- YMCART20190423
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
Clinical Trials on IM19 CAR-T
-
Beijing Immunochina Medical Science & Technology...Not yet recruiting
-
Beijing Immunochina Medical Science & Technology...Recruiting
-
Beijing Immunochina Medical Science & Technology...Unknown
-
Beijing Immunochina Medical Science & Technology...Completed
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingLymphoma | Multiple Myeloma | Acute Lymphoblastic LeukemiaChina
-
Nexcella Inc.Not yet recruitingLight Chain (AL) AmyloidosisUnited States
-
Bellicum PharmaceuticalsSuspendedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein OverexpressionUnited States
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Chunrui LiNanjing IASO Biotechnology Co., LtdRecruitingPlasma Cell Leukemia | Relapsed/Refractory Multiple MyelomaChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States